50-76-0

• 常用中文名：放线菌素D
• 常用英文名：Actinomycin D
• CAS号：50-76-0
• 分子式：C₆₂H₈₆N₁₂O₁₆
• 分子量：1255.417
• 相关类别： 原料药 抗肿瘤药 抗生素类抗肿瘤药
• 发布时间：2018-02-04 08:00:00
• 更新时间：2026-07-01 08:15:43
• Actinomycin D 抑制 DNA 修复,IC50 为 0.42 μM。

名称

• 中文名: 放线菌素D
• 英文名: actinomycin D
• 中文别名: ACTINOMYCIN D 放线菌素D -01 售完停售; 1,1,3,3-四甲基胍(TMG); 氢氧化钠; 放线菌D; 六亚甲基二胺(1,6-二氨基己烷、1,6-己二胺、HMDA、1,6-已烷二胺、己基亚甲基二胺); 无水磷酸三钠; 放线菌素 IV; 硫酸钡,PURATRONIC|R,(METALSBASIS); Β-巯基丙酸,硫代丙醇酸; 4-硝基苯甲酸((T)); 放线菌素D 标准品; 铜标准溶液(1000ΜG/ML,基体:1.0MOL/LHNO3); 甲酸钠; 十二烷基硫酸钠/月桂基硫酸钠/月桂醇硫酸钠/十二烷基硫酸氢钠/十二醇硫酸钠/发泡粉/十二烷基硫酸酯钠盐/月桂醇硫酸酯钠; 放线菌素D(更生霉素); 邻二氯苯(1MG/ML的甲醇溶液)[用于水分析]; 硬脂胺,1-氨基十八烷,正十八胺,1-十八胺,十八烷胺,氢化牛脂基伯胺,十八烷基伯胺; 2-甲基四氢呋喃,-400PPMBHT作为稳定剂; 碳酸氢钠, 级试剂小苏打; 放线菌素D(5毫克); 丙烯酸羟乙酯,(含200-300PPMMEHQ稳定剂); 放线菌素; 间硝基苯甲酸间硝基苯甲酸间硝基苯甲酸; 过硫酸钾,低氮,最低; 无水硫酸钠,ANHYDROUS,(METALSBASIS); 丙烯酸异丁酯; 更生霉素D; 碳酸氢钠; 放线菌素D 危险品; 过鹏酸钠; 甲酸钾; 更生霉素; 过氧化单硫酸钾盐(CAS号:10-8); 无水磷酸氢钾,ANHYDROUS; 三甲醇丙烷,1,1,1-三羟甲基丙烷,2-乙基-2-羟甲基-1,3-丙二醇; 三氯异氰尿酸(强氯精); 碘酸钾,ACCULUTESTANDDVOLUMETRICSOLUTION,FINALCONCENTRATION0.1N; 尿素; 碳酸氢钾; 硫代硫酸钠无水(,BC); 氯化钙,超干,(METALSBASIS); 放线菌素 D(剧毒) (+4℃); 氧化锆空心球(氧化钙稳定、钙稳定(电熔、化学)、钇稳定); DNA修复抑制剂(ACTINOMYCIN D); 放线菌素-D; 草酸草酸, 0.05 M 水溶液; 更生霉素,DACTINOMYCIN; 放线菌素D (10MM IN DMSO); 硫化剂双-25; 放线菌素C1; ACTINOMYCIN D (DACTINOMYCIN),NUCLEIC ACID AND蛋白SYNTHESIS抑制剂; DI-N-丁基马来酸酯; 放线菌素 D 溶液 来源于链霉菌 属; 更生霉素-有毒产品; 碳酸锰(II),PURATRONIC,(METALSBASIS); 草酸试剂; 丙烯酸-2-乙基己酯单体(含稳定剂MEHQ)
• 英文别名: 2-Amino-N,N'-bis[(6S,9R,10S,13R,18aS)-6,13-diisopropyl-2,5,9-trimethyl-1,4,7,11,14-pentaoxohexadecahydro-1H-pyrrolo[2,1-i][1,4,7,10,13]oxatetraazacyclohexadecin-10-yl]-4,6-dimethyl-3-oxo-3H-phenoxazine-1,9-dicarboxamide; 2-Amino-N,N'-bis[hexadecahydro-2,5,9-trimethyl-6,13-bis(1-methylethyl)-1,4,7,11,14-pentaoxo-1H-pyrrolo[2,1-i][1,4,7,10,13]oxatetraazacyclohexadecin-10-yl]-4,6-dimethyl-3-oxo-3H-phenoxazine-1,9-dicboxamide; 3H-Phenoxazine-1,9-dicboxamide, 2-amino-N,N'-bis(hexadecahydro-6,13-diisopropyl-2,5,9-trimethyl-1,4,7,11,14-pentaoxo-1H-pyrrolo[2,1-i][1,4,7,10,13]oxatetraazacyclohexadecin-10-yl)-4,6-dimethyl-3-oxo; 2-Amino-4,6-dimethyl-3-oxo-N,N'-bis[(6S,9R,10S,13R,18aS)-2,5,9-trimethyl-6,13-bis(1-methylethyl)-1,4,7,11,14-pentaoxohexadecahydro-1H-pyrrolo[2,1-i][1,4,7,10,13]oxatetraazacyclohexadecin-10-yl]-3H-phe; Actinomycin X1; CACTINOMYCIN; actinomycini(sub1); MFCD00070921; 6-dimethyl-3-oxo-xatetra-azacyclohexadecin-10-yl); actinomycinaiv; Actinomycin D, Actinomycin IV, Actinomycin C1, Dactinomycin; Actinomycin C1; oncostatink; acto-d; dilactoneactinomycindioicdacid; Actinomycin C1, ActinomycinIV, Dactinomycin; stereoisomerofn,n’-((2-amino-4,6-dimethyl-3-oxo-3h-phenoxazine-1,9-diyl)bis(; Dactinomycin (50 mg); Acto-D; Chounghwamycin B; actinomycini1; chounghwamycinb; 2-Amino-4,6-dimethyl-3-oxo-N,N'-bis[(6S,9R,10S,13R,18aS)-2,5,9-trimethyl-6,13-bis(1-methylethyl)-1,4,7,11,14-pentaoxohexadecahydro-1H-pyrrolo[2,1-i][1,4,7,10,13]oxatetraazacyclohexadecin-10-yl]-3H-phenoxazin-1,9-dicarboxamid; Dilactone actinomycin D acid; ACTINOMYCIN C, STRTOMYCES CHRYSOMALLUS; Actinomycin D(8CI,9CI); AD(VAN); Oncostatin K; ACTINOMYCIN IV; actinomycin7; Actinomycin D,Actinomycin C1, ActinomycinIV, Dactinomycin; ACTINOMYCIN D extrapure for biochemistry; 1-oxo-2,1-ethanediyl)-1,2-pyrrolidinediylcbonyl(methylimino)(1-oxo-2,1-ethan; actd; ACTINOMYCIN D CELL CULTURE; dactinomycin; Dactinomycin, DTM; cosmegen; Actinomycin D, Strtomyces sp. - - Calbiochem; noxazin-1,9-dicarboxamid; nci-c04682; ACTINOMYCIN D FROM STRTOMYCES SP; 2-amino-4,6-diméthyl-3-oxo-N,N'-bis[(6S,9R,10S,13R,18aS)-2,5,9-triméthyl-6,13-bis(1-méthyléthyl)-1,4,7,11,14-pentaoxohexadécahydro-1H-pyrrolo[2,1-i][1,4,7,10,13]oxatétraazacyclohexadécin-10-yl]-3H-phé; EINECS 200-063-6; Actinomycin AIV; Actactinomycin A IV; l-6,13-bis(1-methylethyl)-1,4,7,11,14-pentaoxo-1h-pyrrolo(2,1-i)(1,4,7,10,13)o; nsc3053; 2-amino-4,6-dimethyl-3-oxo-N,N'-bis[(6S,9R,10S,13R,18aS)-2,5,9-trimethyl-6,13-bis(1-methylethyl)-1,4,7,11,14-pentaoxohexadecahydro-1H-pyrrolo[2,1-i][1,4,7,10,13]oxatetraazacyclohexadecin-10-yl]-3H-phenoxazine-1,9-dicarboxamide; ACTINOMYCIN % FROM STRTOMYCES PVULUS; 2-Amino-(N,N)-1-bis(hexadecahydro-6,13-diisopropyl-2,5,9-trimethyl-1,4,7,11,14-pentaoxo-1H-pyrrolo[2,1]-[1,4,7,10,13]oxatetraazacyclohexadecin-10-yl)-4,6-dimethyl-3-oxo-3H-phenoxazine-1,9-dicboxamide; 2-amino-4,6-dimethyl-3-oxo-N,N'-bis[(6S,9R,10S,13R,18aS)-2,5,9-trimethyl-1,4,7,11,14-pentaoxo-6,13-di(propan-2-yl)hexadecahydro-1H-pyrrolo[2,1-i][1,4,7,10,13]oxatetraazacyclohexadecin-10-yl]-3H-phenoxazine-1,9-dicarboxamide; meractinomycin; Cosmogen; MERACTINOMYCIN; Actinomycin I1; 1-ethanediyl)imino(2-(1-methylethyl)-cbonylimino(2-(1-hydroxyethyl)-1-oxo; Actinomycin DDactinomycin; DACTINOMYCIN; Actinomycin C1, Dactinomycin; lyovaccosmegen; (-)-ACTINOMYCIN D; 2-amino-4,6-diméthyl-3-oxo-N,N'-bis[(6S,9R,10S,13R,18aS)-2,5,9-triméthyl-6,13-bis(1-méthyléthyl)-1,4,7,11,14-pentaoxohexadécahydro-1H-pyrrolo[2,1-i][1,4,7,10,13]oxatétraazacyclohexadécin-10-yl]-3H-phénoxazine-1,9-dicarboxamide; actinomycindioicdacid,dilactone; actinomycin11cosmegen; dactinomycind; dilactoneactinomycindacid; ACT; actinomycin-(thre-val-pro-s-meval); noxazine-1,9-dicarboxamide; actinomycinx1; 8-Amino-N-(2-amino-4,6-dimethyl-3-oxo-phenoxazin-1-yl)carbonyl-N'-[8-amino-4,6-dimethyl-7-oxo-9-[[3,6,10-trimethyl-7,14-bis(1-methylethyl)-2,5,8,12,15-pentaoxo-9-oxa-3,6,13,16-tetrazabicyclo[14.3.0]nonadec-11-yl]cbamoyl]phenoxazin-1-yl]carbonyl-4,6-dime; nci-co4682; Dactinomycin(USAN); 3h-phenoxazine-1,9-dicboxamide,2-amino-n,n’-bis(hexadecahydro-2,5,9-trimethy; ediyl)))bis(n-methyl-l-valine)di-xi-lactone

物化性质

• 密度: 1.4±0.1 g/cm3
• 沸点: 1386.0±65.0 °C at 760 mmHg
• 熔点: 251-253 °C
• 分子式: C₆₂H₈₆N₁₂O₁₆
• 分子量: 1255.417
• 闪点: 792.1±34.3 °C
• 精确质量: 1254.628418
• PSA: 359.98000
• LogP: -4.03
• 外观性状: 红色结晶粉末
• 蒸汽压: 0.0±0.3 mmHg at 25°C
• 折射率: 1.656
• 储存条件:

  密封4℃干燥避光保存。

• 稳定性: Stable, but light sensitive, especially in dilute solution. Incompatible with strong acids, strong bases, strong oxidizing agents. Combustible.
• 水溶解性: SOLUBLE
• 计算化学:

  1、 疏水参数计算参考值（XlogP）：3.8

  2、 氢键供体数量：5

  3、 氢键受体数量：18

  4、 可旋转化学键数量：8

  5、 互变异构体数量：64

  6、 拓扑分子极性表面积（TPSA）：356

  7、 重原子数量：90

  8、 表面电荷：0

  9、 复杂度：3030

  10、同位素原子数量：0

  11、确定原子立构中心数量：0

  12、不确定原子立构中心数量：10

  13、确定化学键立构中心数量：0

  14、不确定化学键立构中心数量：0

  15、共价键单元数量：1

• 更多:

  1. 性状：鲜红色结晶性粉末，无臭，有吸湿性。遇光；热或氧化剂均能使其效价降低。

  2. 密度（g/mL,25/4℃）：未确定

  3. 相对蒸汽密度（g/mL,空气=1）：未确定

  4. 熔点（ºC）：251-253°C

  5. 沸点（ºC,常压）：未确定

  6. 沸点（ºC, 5.2 kPa）：未确定

  7. 折射率：未确定

  8. 闪点（ºC）：未确定

  9. 比旋光度（º）：[α]¹⁸_D-315°(0.02%，甲醇)

  10. 自燃点或引燃温度（ºC）：未确定

  11. 蒸气压（kPa,25 ºC）：未确定

  12. 饱和蒸气压（kPa,60 ºC）：未确定

  13. 燃烧热（KJ/mol）：未确定

  14. 临界温度（ºC）：未确定

  15. 临界压力（KPa）：未确定

  16. 油水（辛醇/水）分配系数的对数值：未确定

  17. 爆炸上限（%,V/V）：未确定

  18. 爆炸下限（%,V/V）：未确定

  19. 溶解性：未溶于石油醚，微溶于水，溶于甲醇、乙醇及乙酸乙酯，易溶于苯、氯仿和丙酮。

生物活性

• 描述: Actinomycin D 抑制 DNA 修复,IC50 为 0.42 μM。
• 相关类别:
  信号通路 >> 自噬 >> 自噬
  信号通路 >> 细胞周期/DNA损伤 >> DNA/RNA合成
  天然产物 >> 其他
  研究领域 >> 癌症
• 靶点:

  IC50: 0.42 μM (DNA repair)[1]

• 体外研究: 放线菌素D是DNA转录和复制的抑制剂[1]。放线菌素D通过抑制80nM的BrdU掺入显着降低血管平滑肌细胞(SMC)的增殖。使用流式细胞分析进一步支持G1期阻滞。放线菌素D非常有效,抑制浓度IC50为0.4nM,而致死剂量LD50为260μM。增殖细胞核抗原(PCNA),粘着斑激酶(FAK)和Raf的蛋白表达水平均被放线菌素D抑制。细胞周期信号调节激酶(Erk)参与细胞周期停滞,发现放线菌素D增加[2]。
• 体内研究: 将含有80nM和80μM放线菌素D的pluronic凝胶局部施用以包围大鼠颈动脉外膜,新内膜的厚度显着减少(分别为45％和55％)[2]。放线菌素D和氟达拉滨组中的小鼠比对照组寿命显着更长,P值分别<0.001和0.007。有趣的是,单用放线菌素D治疗总体生存率优于氟达拉滨(P = 0.026)[3]。
• 激酶实验: 将放线菌素D在30℃下与含有以下物质的反应混合物共孵育3小时：120mg HeLa细胞的全细胞提取物，70mM KCl，dGTP，dCTP，dATP和地高辛化-dUTP各0.4mM。反应缓冲液含有40mM Hepes-KOH（pH 7.6），5mM MgCl 2,0.5mM二硫苏糖醇，2mM EGTA，10mM磷酸肌酸，50mg / mL磷酸肌酸和360mg / mL牛血清白蛋白。在该反应过程中，识别DNA损伤并且切除的贴片被新合成的DNA片段替换。在整个DNA合成中，掺入了地高辛化的dUMP。通过三次洗涤终止DNA修复反应[1]。
• 动物实验: 小鼠[3]将原始Eμ-TCL1a转基因小鼠与C57BL / 6小鼠回交> 9代.C57BL / 6野生型小鼠植入来自Eμ-TCL-1转基因小鼠的肿瘤细胞。通过从尾静脉采血并通过流式细胞术分析，在小鼠中常规检查外周血中CD5 + / CD19 +细胞的百分比。当外周血中肿瘤细胞的百分比达到40-60％时，开始治疗。每天通过ip注射施用放线菌素D（0.06mg / kg，10天）。
• 参考文献:

  [1]. Barret JM, et al. Evaluation of DNA repair inhibition by antitumor or antibiotic drugs using a chemiluminescence microplateassay. Carcinogenesis. 1997 Dec;18(12):2441-5.

  [2]. Wu CH, et al. The molecular mechanism of actinomycin D in preventing neointimal formation in rat carotid arteries after balloon injury. J Biomed Sci. 2005;12(3):503-12.

  [3]. Merkel O, et al. Actinomycin D induces p53-independent cell death and prolongs survival in high-risk chronic lymphocytic leukemia. Leukemia. 2012 Dec;26(12):2508-16.

MSDS

Name: Actinomycin D Material Safety Data Sheet Synonym: Dactinomycin CAS: 50-76-0 Section 1 - Chemical Product MSDS Name:Actinomycin D Material Safety Data Sheet Synonym:Dactinomycin Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS CAS# Chemical Name content EINECS# 50-76-0 Actinomycin D 100.0 200-063-6 Hazard Symbols: T+ Risk Phrases: 28 Section 3 - HAZARDS IDENTIFICATION EMERGENCY OVERVIEW Very toxic if swallowed.Light sensitive. Potential Health Effects Eye: May cause severe eye irritation. May cause eye injury. Skin: May cause skin sensitization, an allergic reaction, which becomes evident upon re-exposure to this material. Ingestion: May be fatal if swallowed. May cause gastrointestinal irritation with nausea, vomiting and diarrhea. Inhalation: May cause respiratory tract irritation. May cause effects similar to those described for ingestion. Inhalation may produce coughing, nausea, and pulmonary edema. Chronic: Repeated exposure may cause sensitization dermatitis. Section 4 - FIRST AID MEASURES Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid immediately. Skin: Get medical aid if irritation develops or persists. Wash clothing before reuse. Flush skin with plenty of soap and water. Destroy contaminated shoes. Ingestion: Call a poison control center. If swallowed, do not induce vomiting unless directed to do so by medical personnel. Never give anything by mouth to an unconscious person. Get medical aid. Inhalation: Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid if cough or other symptoms appear. Do NOT use mouth-to-mouth resuscitation. Notes to Physician: Treat symptomatically and supportively. Section 5 - FIRE FIGHTING MEASURES General Information: As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion. Extinguishing Media: Use water spray, dry chemical, carbon dioxide, or chemical foam. Section 6 - ACCIDENTAL RELEASE MEASURES General Information: Use proper personal protective equipment as indicated in Section 8. Spills/Leaks: Wash area with soap and water. Clean up spills immediately, observing precautions in the Protective Equipment section. Sweep up, then place into a suitable container for disposal. Avoid generating dusty conditions. Provide ventilation. Section 7 - HANDLING and STORAGE Handling: Wash thoroughly after handling. Use with adequate ventilation. Minimize dust generation and accumulation. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation. Storage: Do not store in direct sunlight. Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances. Keep refrigerated. (Store below 4C/39F.) Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION Engineering Controls: Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low. Use only under a chemical fume hood. Exposure Limits CAS# 50-76-0: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166. Skin: Wear appropriate protective gloves to prevent skin exposure. Clothing: Wear appropriate protective clothing to prevent skin exposure. Respirators: Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced. Section 9 - PHYSICAL AND CHEMICAL PROPERTIES Physical State: Powder Color: red Odor: none reported pH: Not available. Vapor Pressure: Not available. Viscosity: Not available. Boiling Point: Not available. Freezing/Melting Point: 245-252C Autoignition Temperature: Not applicable. Flash Point: 241 deg C ( 465.80 deg F) Explosion Limits, lower: Not available. Explosion Limits, upper: Not available. Decomposition Temperature: 250 deg C Solubility in water: In methanol Specific Gravity/Density: Molecular Formula: C62H86N12O16 Molecular Weight: 1255.5 Section 10 - STABILITY AND REACTIVITY Chemical Stability: Stable under normal temperatures and pressures. Conditions to Avoid: Incompatible materials, light, dust generation, excess heat. Incompatibilities with Other Materials: Strong oxidizing agents, strong bases, strong acids Hazardous Decomposition Products: Nitrogen oxides, carbon monoxide, irritating and toxic fumes and gases, carbon dioxide. Hazardous Polymerization: Has not been reported Section 11 - TOXICOLOGICAL INFORMATION RTECS#: CAS# 50-76-0: AU1575000 LD50/LC50: CAS# 50-76-0: Oral, mouse: LD50 = 13 mg/kg; Oral, mouse: LD50 = 20 mg/kg; Oral, rat: LD50 = 7200 ug/kg. Carcinogenicity: Actinomycin D - California: carcinogen, initial date 10/1/89 Other: See actual entry in RTECS for complete information. Section 12 - ECOLOGICAL INFORMATION Section 13 - DISPOSAL CONSIDERATIONS Products which are considered hazardous for supply are classified as Special Waste and the disposal of such chemicals is covered by regulations which may vary according to location. Contact a specialist disposal company or the local waste regulator for advice. Empty containers must be decontaminated before returning for recycling. Section 14 - TRANSPORT INFORMATION IATA No information available. IMO No information available. RID/ADR No information available. Section 15 - REGULATORY INFORMATION European/International Regulations European Labeling in Accordance with EC Directives Hazard Symbols: T+ Risk Phrases: R 28 Very toxic if swallowed. Safety Phrases: S 1 Keep locked up. S 45 In case of accident or if you feel unwell, seek medical advice immediately (show the label where possible). WGK (Water Danger/Protection) CAS# 50-76-0: 3 Canada None of the chemicals in this product are listed on the DSL/NDSL list. CAS# 50-76-0 is not listed on Canada's Ingredient Disclosure List. US FEDERAL TSCA CAS# 50-76-0 is not listed on the TSCA inventory. It is for research and development use only. SECTION 16 - ADDITIONAL INFORMATION N/A

安全

• 符号: GHS06
• 信号词: Danger
• 危害声明: H300
• 警示性声明: P264-P301 + P310
• 个人防护装备: Eyeshields;Faceshields;full-face particle respirator type N100 (US);Gloves;respirator cartridge type N100 (US);type P1 (EN143) respirator filter;type P3 (EN 143) respirator cartridges
• 危害码 (欧洲): T+:Verytoxic;
• 风险声明 (欧洲): R28;R40;R61
• 安全声明 (欧洲): S53-S36/37/39-S45-S1-S36/37-S28-S22
• 危险品运输编码: UN 3462 6.1/PG 2
• WGK德国: 3
• RTECS号: AU1575000
• 包装等级: II
• 危险类别: 6.1(a)
• 海关编码: 29419000

合成路线

上下游产品

上游产品  4
2441-62-5 6041-34-5 27483-27-8 6686-01-7
下游产品  0

制备

该品是由放线菌产生的多肽抗生素。我国从桂林土壤中分离出Str. melanochromogehes菌株的发酵液中提取的产品称更生霉素，与国外报道的放线菌素D相同。

海关

海关编码	29419000